ASX:EQT
ASX:EQTCapital Markets

3 ASX Dividend Stocks With Up To 4.2% Yield

The Australian market is navigating a cautious landscape, with ASX futures showing slight declines following mixed performances on Wall Street and concerns over recent inflation data. In this environment, dividend stocks can offer investors a measure of stability and income, making them an attractive option for those looking to balance potential market volatility.
ASX:ELS
ASX:ELSElectronic

3 ASX Growth Stocks With Insider Ownership Up To 33%

The Australian market has been experiencing cautious movements, with ASX futures slightly down overnight, reflecting concerns from a recent hotter-than-expected CPI read. In this environment of uncertainty and mixed global signals, growth companies with high insider ownership can be particularly attractive as they often indicate strong confidence from those who know the business best.
ASX:ZIM
ASX:ZIMMetals and Mining

Exploring Australian United Investment And 2 Other Promising Small Caps

As the Australian market navigates a cautious landscape, influenced by mixed performances on Wall Street and concerns over recent economic indicators like the hotter-than-expected CPI read, investors are keeping a close eye on small-cap opportunities. In such an environment, identifying promising stocks often involves looking for companies with strong fundamentals and growth potential that can weather broader market uncertainties.
ASX:DYL
ASX:DYLOil and Gas

Cettire Leads 3 ASX Penny Stocks Worth Watching

The Australian market is currently navigating a cautious landscape, with ASX futures reflecting concerns over recent inflation data and the looming US Federal Reserve decision. In such an environment, identifying stocks that balance affordability with growth potential becomes crucial. While the term "penny stocks" may seem outdated, these investments can still offer valuable opportunities when they are supported by strong financials and strategic positioning.
ASX:MTM
ASX:MTMMetals and Mining

Why Metallium (ASX:MTM) Is Up 47.8% After Securing Exclusive Rights to Refine Critical Rare Earths

New Frontier Minerals Ltd. recently announced a collaboration with Metallium Ltd., where Metallium's proprietary Flash Joule Heating technology achieved exceptional enrichment of dysprosium and terbium from Harts Range ore in Australia. This agreement grants Metallium exclusive, long-term rights to apply its advanced refining process to all Harts Range material, securing potential royalty and licensing revenue from future production. We’ll explore how exclusive processing rights for critical...
ASX:NHC
ASX:NHCOil and Gas

How Technical Downtrend and New Production Forecasts at New Hope (ASX:NHC) Have Changed Its Investment Story

New Hope Corporation Limited recently received shareholder approval for amendments to its Constitution and reported quarterly group coal production for the quarter ended October 31, 2025, alongside issuing new production guidance for fiscal 2026. Technical analysis has spotlighted New Hope Corporation as experiencing excess supply and downward price pressure, drawing increased interest from market participants. We’ll assess how the technical downtrend flagged by analysts shapes New Hope’s...
ASX:PRU
ASX:PRUMetals and Mining

Does Perseus Mining's (ASX:PRU) Share Buy-Back Reflect Strategic Confidence or Caution?

Perseus Mining Limited announced in the past week that its Board has authorized a new on-market share buy-back program, aiming to repurchase up to 40,000,000 shares (2.96% of its share capital) for up to A$100 million, set to continue through August 28, 2026. This initiative marks a clear signal of the company’s focus on capital management and reinforces management’s confidence in Perseus Mining’s financial and operational outlook. We’ll explore how the newly authorized buy-back could...
ASX:MSB
ASX:MSBBiotechs

Mesoblast (ASX:MSB) Is Up 17.3% After Lifting Revenue Guidance and Announcing NIH Trial Collaboration Has The Bull Case Changed?

Mesoblast Limited recently released updated revenue guidance, projecting gross revenue of over US$30.0 million from Ryoncil® sales for the quarter ending December 31, 2025, and announced a collaborative pivotal trial with the NIH-funded Blood and Marrow Transplant Clinical Trials Network for Ryoncil® in adults with severe acute graft versus host disease. This combination of higher sales forecasts and expanded clinical research signals an important step as Mesoblast seeks to broaden both its...
ASX:AX1
ASX:AX1Specialty Retail

Does Accent Group’s (ASX:AX1) Transparent MySale Losses Reveal a New Approach to Cost Discipline?

Earlier this month, Accent Group Limited released updated earnings guidance for the 2026 financial year, forecasting first half EBIT in the A$55 million to A$60 million range and full-year EBIT between A$85 million and A$95 million, accounting for nonrecurring losses from closing its MySale operations. A unique aspect of this update is the explicit inclusion of nonrecurring losses tied to the MySale closure, providing a more transparent view of the company’s operational expectations and cost...